Abstract CT184: First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis-Reference-Cited by-同舟云学术

Abstract CT184: First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis

Published:2021-07-01 Issue: Volume: Page:
ISSN:
Container-title:Clinical Trials
language:
Short-container-title:

Author:

Shen Lin,Bai Yuxian,Lin Xiaoyan,Li Wei,Wang Jufeng,Zhang Xiaochun,Pan Hongming,Bai Chunmei,Bai Li,Cheng Ying,Zhang Jingdong,Zhong Haijun,Ba Yi,Hu Wenwei,Xu Ruihua,Guo Weijian,Qin Shukui,Yang Nong,Lu Jianwei,Shitara Kohei,Lei Ming,Li Mingshun,Bao Nicole,Chen Tian,Liu Tianshu

Publisher

American Association for Cancer Research

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the efficacy between immunochemotherapy and chemotherapy in gastric cancer accompanied with synchronous liver metastases: A real‐world retrospective study;Cancer Medicine;2023-04-16

2. Real‐world clinical outcomes of the combination of anti‐PD‐1 antibody, trastuzumab, and chemotherapy for HER2‐positive gastric/gastroesophageal junction cancer;Cancer Medicine;2023-03-13

3. Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review;JCO Oncology Practice;2023-03

4. Research Progress of PD-1/PD-L1 Inhibitors in the Treatment of Advanced Gastric Carcinoma;Advances in Clinical Medicine;2023

5. Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review;Frontiers in Oncology;2022-11-24